FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsHigh accuracy mutation detection in leukemia on a selected panel of cancer genesIdentification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.Gain-of-function CCR4 mutations in adult T cell leukemia/lymphomaComprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemiaEmerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesJanus kinase 3: the controller and the controlledWhole-genome sequencing reveals oncogenic mutations in mycosis fungoides.HTLV-I Tax-Mediated Inactivation of Cell Cycle Checkpoints and DNA Repair Pathways Contribute to Cellular Transformation: "A Random Mutagenesis Model"Disease-specific mutations in mature lymphoid neoplasms: recent advances.STAT3 inhibitors: finding a home in lymphoma and leukemia.Profile of pacritinib and its potential in the treatment of hematologic disorders.Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained.A three-signal model of T-cell lymphoma pathogenesisMature T-cell leukemias: Molecular and Clinical Aspects.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogrammingJAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.HiJAKing the epigenome in leukemia and lymphoma.p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation.A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.Advances in the understanding and management of T-cell prolymphocytic leukemia.The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling.Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
P2860
Q26782539-8E067597-CEEB-4796-ACC9-AFD58B808DD2Q28728910-0D711984-2231-43EC-8F3F-9B727D32CBF6Q33798544-EB913C06-2ECF-488C-9681-AF60D1CCF8E2Q34648812-FFCF4AE5-2E50-4DA8-9209-4C38F3BD2FF7Q34708318-3E0DC0DC-D312-43D2-8D3E-B96054A6185DQ35075158-27D1636C-C45F-4814-B3E5-8EB2E2575EB9Q35132241-7CDD8813-CF81-4F3E-82FC-BA487C835A44Q35770946-48331950-142A-4DB8-A0FC-9DD3FF3C87FFQ35884253-380CAF16-C21F-4FBB-A3FD-2915CC902A26Q36509597-4069B17F-3068-4050-86F8-7459D12BD8E5Q38201143-DAAEF8C9-A384-4E7A-B1EC-24997BABECDAQ38202556-073940EA-AD1D-404E-866C-B6A6E50F934CQ38244524-51D2A7FB-1D15-4D1F-BE8E-59D82C3F1B6BQ38259670-B7F237E0-D5B5-49BD-83E4-1E454D9E439DQ38593164-195BB5F6-3019-4EBD-B1CC-41B1AA59EBD3Q38598546-5F991465-C584-4E81-A8B4-8B0E3D534C9BQ38751230-3AC392E7-7A89-4C99-B125-7400AC0402E5Q39064213-F5EC9B9F-83AE-4E86-AA7B-C2D2BE31642AQ39142126-1550A21F-B33D-42E9-B553-16ED120ADE22Q39149556-ECAEC29E-BA2B-4005-97F7-7E93F26C5BC8Q39237403-55B72A0B-7A43-4B7B-AB2F-EE8EFA5E8E3BQ42341711-34382790-25DA-4881-A186-E2132F75E170Q43135354-D3ED3C79-95F5-450E-B9B4-2EFD79082B5EQ47113632-9BFFB101-AB52-40EA-B264-34543DDAF2AAQ47147269-15D90870-4F10-4849-828E-1F87177F9173Q54342283-E34FAF89-5014-420D-949E-3812C729EC0CQ54982413-09A1F5A7-F26C-4489-B2E9-46E8E24C6269Q55281964-A81F7B00-4E7B-4A89-B539-44B5EB831463
P2860
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
@ast
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
@en
type
label
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
@ast
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
@en
prefLabel
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
@ast
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
@en
P2093
P2860
P1433
P1476
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
@en
P2093
John Janik
Natalina E Elliott
Susan M Cleveland
Thomas A Waldmann
Utpal P Davé
Victor Grann
P2860
P304
P356
10.1182/BLOOD-2010-12-319467
P407
P577
2011-08-05T00:00:00Z